Cure My Disease

Don't miss your cure!

 Log in / Sign up

Morning vs. afternoon: timing of immunotherapy may impact lung cancer outcomes

NCT ID NCT07251582

Knowledge-focused Sponsor: Hunan Province Tumor Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it works for people with stage II-III lung cancer before surgery. About 156 participants will receive standard treatment plus immunotherapy at different times of day. The goal is to see which timing leads to better tumor shrinkage and longer survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 186 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria: 1. Age ≥18 and ≤75 years at the time of enrollment. 2. Histologically or cytologically confirmed diagnosis of resectable stage II to III non-small cell lung cancer (NSCLC). 3. Deemed suitable for neoadjuvant immunotherapy combined with platinum-based chemotherapy and subsequent surgical resection based on multidisciplinary team (MDT) assessment. 4. ECOG Performance Status of 0 or 1. 5. No prior systemic antitumor therapy for the current NSCLC diagnosis. 6. Adequate bone marrow, hepatic, renal, and cardiac function based on local laboratory standards. 7. Willing and able to comply with scheduled visits, treatment plans, and other study procedures. 8. Signed informed consent prior to participation. Exclusion Criteria: Participants meeting any of the following criteria will be excluded: 1. Presence of EGFR-sensitive mutations (e.g., exon 19del, L858R) or ALK/ROS1 rearrangements. 2. Presence of uncontrolled or symptomatic brain metastases. 3. History of any other malignancy within 3 years prior to enrollment, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ. 4. History of prior systemic therapy (immunotherapy, chemotherapy, or targeted therapy) for lung cancer. 5. Known severe allergic reactions to PD-1 or PD-L1 inhibitors (Grade ≥3 by CTCAE). 6. Active autoimmune disease requiring systemic immunosuppression. 7. Active infections, including active HBV, HCV, or HIV infection. 8. Pregnant or breastfeeding women. 9. Any comorbid condition or uncontrolled illness that, in the opinion of the investigator, may interfere with study participation or pose unacceptable risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Resectable stage II-III non-small cell lung cancer (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Resectable stage II-III non-small cell lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hunan Cancer hospital

    RECRUITING

    Changsha, Hunan, China

  • Hunna Cancer Hospital, Clinical Trails Center

    RECRUITING

    Changsha, Hunan, 410013, China